Literature DB >> 23443851

p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.

Xin Zhou1.   

Abstract

p73 gene shares structural and functional similarities to p53 and plays an important role in modulating cell cycle arrest and apoptosis. A common non-coding polymorphism of p73 G4C14-to-A4T14 (rs2273953 and rs1801173) at exon 2 may affect gene expression, thus, it may lead to functional significance. The correlation of this polymorphism with clinicopathologic variables of patients with breast cancer has not been investigated. In this study, single-nucleotide polymorphisms (SNPs) of p73 G4C14-to-A4T14 were genotyped by Sequenom MassArray-iPLEX GOLD System in 170 patients with breast cancer. Data were analyzed via t test, chi-square test, and logistic regression analysis. There was no significant correlation between p73 G4C14-to-A4T14 polymorphisms and the patient characteristics, such as clinical TNM stage, menopausal status, axillary lymph node metastasis, pathological type, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2). No significant relationship was observed between the p73 G4C14-to-A4T14 polymorphism and p73 protein expression in cancer tissues. The frequency of GC/GC genotype in patients with triple-negative breast cancer (TNBC) was 78.9 %, that of patients with others was 57.6 %, and the difference had statistical significance (χ ( 2 ) = 5.74, P = 0.02). p73 G4C14-to-A4T14 polymorphisms were negatively correlated with chemosensitivity for anthracycline-based chemotherapy in breast cancer (P > 0.05). p73 G4C14-to-A4T14 polymorphisms are positively correlated with TNBC, and p73 gene may play a critical role in a novel therapeutic strategy to TNBC. Additional larger studies are required to test these hypotheses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23443851     DOI: 10.1007/s12032-013-0515-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  46 in total

1.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.

Authors:  Elsa R Flores; Kenneth Y Tsai; Denise Crowley; Shomit Sengupta; Annie Yang; Frank McKeon; Tyler Jacks
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer.

Authors:  Xin-En Huang; Nobuyuki Hamajima; Nobuyuki Katsuda; Keitaro Matsuo; Kaoru Hirose; Mitsuhiro Mizutani; Hiroji Iwata; Shigeto Miura; Jin Xiang; Shinkan Tokudome; Kazuo Tajima
Journal:  Breast Cancer       Date:  2003       Impact factor: 4.239

4.  Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population.

Authors:  Yan Shi; Ping Xiang; Li Li; Min Shen
Journal:  Forensic Sci Int       Date:  2010-11-10       Impact factor: 2.395

5.  [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].

Authors:  Peng Yuan; Xiao-ping Miao; Xue-mei Zhang; Zhong-hua Wang; Wen Tan; Xiang-ru Zhang; Yan Sun; Bing-he Xu; Dong-xin Lin
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2006-02

6.  Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma.

Authors:  H Takahashi; S Ichimiya; Y Nimura; M Watanabe; M Furusato; S Wakui; R Yatani; S Aizawa; A Nakagawara
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

Review 7.  The promise of cancer genetics.

Authors:  D A Haber; E R Fearon
Journal:  Lancet       Date:  1998-05       Impact factor: 79.321

8.  p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies.

Authors:  Fei Liu; Liu Liu; Bo Li; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen; Ming-Qing Xu; Wen-Tao Wang; Jia-Yin Yang
Journal:  Mutagenesis       Date:  2011-04-18       Impact factor: 3.000

9.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

10.  TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease.

Authors:  Quanyi Li; Eleni S Athan; Michelle Wei; Eric Yuan; Samuel L Rice; Jean-Paul Vonsattel; Richard P Mayeux; Benjamin Tycko
Journal:  BMC Med Genet       Date:  2004-06-02       Impact factor: 2.103

View more
  3 in total

1.  The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.

Authors:  Chunbo Wang; Huan Nie; Yiqun Li; Guiyou Liu; Xu Wang; Shijie Xing; Liping Zhang; Xin Chen; Yue Chen; Yu Li
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

2.  Association between the p73 gene G4C14-to-A4T14 single nucleotide polymorphism and risk of cervical cancer by high resolution melting and PCR with confronting two-pair primers in a Chinese population.

Authors:  Haiyan Guo; Shaodi Yang; Lijian Xu; Ding Li; Jianxin Tang; Shuangshaung Wang; Benjie Wei; Zhengchun Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

3.  Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance.

Authors:  L Michael Carastro; Hui-Yi Lin; Hyun Y Park; Donghwa Kim; Selina Radlein; Kaia K Hampton; Ardeshir Hakam; Babu Zachariah; Julio Pow-Sang; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.